These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30123104)

  • 21. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology.
    Laurent C; Eddarkaoui S; Derisbourg M; Leboucher A; Demeyer D; Carrier S; Schneider M; Hamdane M; Müller CE; Buée L; Blum D
    Neurobiol Aging; 2014 Sep; 35(9):2079-90. PubMed ID: 24780254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular biomarkers of Alzheimer's disease.
    Heaton GR; Davis BM; Turner LA; Cordeiro MF
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):117-25. PubMed ID: 25788142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer's disease.
    Uddin MS; Kabir MT; Tewari D; Mathew B; Aleya L
    Sci Total Environ; 2020 Jan; 700():134836. PubMed ID: 31704512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease.
    Islam Khan R; Nirzhor SSR; Rashid B
    Brain Sci; 2018 Aug; 8(9):. PubMed ID: 30149687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes.
    Hamilton A; Zamponi GW; Ferguson SS
    Mol Brain; 2015 Mar; 8():18. PubMed ID: 25888324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas.
    den Haan J; Morrema THJ; Verbraak FD; de Boer JF; Scheltens P; Rozemuller AJ; Bergen AAB; Bouwman FH; Hoozemans JJ
    Acta Neuropathol Commun; 2018 Dec; 6(1):147. PubMed ID: 30593285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20-APP transgenic and wild-type mice.
    Tapia-Rojas C; Inestrosa NC
    J Neurochem; 2018 Feb; 144(4):443-465. PubMed ID: 29240990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Ubiquitin System in Alzheimer's Disease.
    Harris LD; Jasem S; Licchesi JDF
    Adv Exp Med Biol; 2020; 1233():195-221. PubMed ID: 32274758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation.
    Soliman ML; Geiger JD; Chen X
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):163-170. PubMed ID: 27629410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
    Huber CM; Yee C; May T; Dhanala A; Mitchell CS
    J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target.
    Chu J; Praticò D
    Brain Res Bull; 2016 Sep; 126(Pt 2):207-212. PubMed ID: 27005438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Implications of Autophagy in Alzheimer's Disease.
    Hamano T; Hayashi K; Shirafuji N; Nakamoto Y
    Curr Alzheimer Res; 2018; 15(14):1283-1296. PubMed ID: 30289076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies.
    Pereira C; Agostinho P; Moreira PI; Cardoso SM; Oliveira CR
    Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):383-403. PubMed ID: 16101556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.
    Jacobsen JS; Reinhart P; Pangalos MN
    NeuroRx; 2005 Oct; 2(4):612-26. PubMed ID: 16489369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.